Salinomycin Sodium

• CAT Number: I004077
• CAS Number: 55721-31-8
• Molecular Formula: C₄₂H₆₉O₁₁. Na
• Molecular Weight: 772.98
• Purity: ≥95%
• Target: Antibiotic
• Solubility: DMSO: ≥ 35 mg/mL
• Storage: Store at -20°C
• InChI: InChI=1S/C42H70O11.Na/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33;/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)
• InChIKey: YPZYGIQXBGHDBH-UZHRAPRISA-M
• SMILES: CCC(C1CCC(C(O1)C(C)C(C(C)C(=O)C(CC)C2C(CC(C3(O2)C=CC(C4(O3)CCC(O4)(C)C5CCC(C(O5)C)(CC)O)O)C)C)O)C)C(=O)[O-].[Na+]

Salinomycin Sodium (CAT: I004077) is a polyether antibiotic that exhibits potent anticancer properties, particularly against cancer stem cells. It is primarily used as an ionophore that disrupts ion homeostasis in cells, leading to various physiological effects. Salinomycin has been shown to selectively target and eliminate cancer stem cells, which are thought to be responsible for tumor initiation, progression, and resistance to therapy. Additionally, salinomycin exhibits antimicrobial activity against certain pathogens, making it useful in veterinary medicine. Its unique mechanism of action and ability to target cancer stem cells make salinomycin a promising candidate for cancer therapy and stem cell research.

 

Reference

1. Tumour Biol. 2017 Mar;39(3):1010428317695035. doi: 10.1177/1010428317695035.

Salinomycin: A new paradigm in cancer therapy.

Dewangan J(1), Srivastava S(1), Rath SK(1).
Author information:
(1)Genotoxicity Laboratory, Division of Toxicology, CSIR-Central Drug Research
Institute, Lucknow, India.

The primary hurdle in the treatment of cancer is acquisition of resistance by the
tumor cells toward multiple drugs and selectively targeting the cancer stem
cells. This problem was overcome by the chemotherapeutic property of recently
discovered drug salinomycin. Exact mechanism of action of salinomycin is not yet
known, but there are multiple pathways by which salinomycin inhibits tumor
growth. Salinomycin decreases the expression of adenosine triphosphate-binding
cassette transporter in multidrug resistance cells and interferes with Akt
signaling pathway, Wnt/β-catenin, Hedgehog, and Notch pathways of cancer
progression. Salinomycin selectively targets cancer stem cells. The potential of
salinomycin to eliminate both cancer stem cells and therapy-resistant cancer
cells may characterize the compound as a novel and an efficient chemotherapeutic
drug.

2. Curr Med Chem. 2013;20(33):4095-101.

Salinomycin: a novel anti-cancer agent with known anti-coccidial activities.

Zhou S(1), Wang F, Wong ET, Fonkem E, Hsieh TC, Wu JM, Wu E.
Author information:
(1)Department of Pharmaceutical Sciences, North Dakota State University, 203
Sudro Hall, NDSU Dept 2665, PO Box 6050, Fargo, ND 58108-6050. .

Salinomycin, traditionally used as an anti-coccidial drug, has recently been
shown to possess anti-cancer and anti-cancer stem cell (CSC) effects, as well as
activities to overcome multi-drug resistance based on studies using human cancer
cell lines, xenograft mice, and in case reports involving cancer patients in
pilot clinical trials. Therefore, salinomycin may be considered as a promising
novel anti-cancer agent despite its largely unknown mechanism of action. This
review summarizes the pharmacologic effects of salinomycin and presents possible
mechanisms by which salinomycin exerts its anti-tumorigenic activities. Recent
advances and potential complications that might limit the utilization of
salinomycin as an anti-cancer and anti-CSC agent are also presented and
discussed.

3. J Biomed Biotechnol. 2012;2012:950658. doi: 10.1155/2012/950658. Epub 2012 Nov
21.

Salinomycin as a drug for targeting human cancer stem cells.

Naujokat C(1), Steinhart R.
Author information:
(1)Institute of Immunology, University of Heidelberg, Im Neuenheimer Feld 305,
69120 Heidelberg, Germany.

Cancer stem cells (CSCs) represent a subpopulation of tumor cells that possess
self-renewal and tumor initiation capacity and the ability to give rise to the
heterogenous lineages of malignant cells that comprise a tumor. CSCs possess
multiple intrinsic mechanisms of resistance to chemotherapeutic drugs, novel
tumor-targeted drugs, and radiation therapy, allowing them to survive standard
cancer therapies and to initiate tumor recurrence and metastasis. Various
molecular complexes and pathways that confer resistance and survival of CSCs,
including expression of ATP-binding cassette (ABC) drug transporters, activation
of the Wnt/β-catenin, Hedgehog, Notch and PI3K/Akt/mTOR signaling pathways, and
acquisition of epithelial-mesenchymal transition (EMT), have been identified
recently. Salinomycin, a polyether ionophore antibiotic isolated from
Streptomyces albus, has been shown to kill CSCs in different types of human
cancers, most likely by interfering with ABC drug transporters, the Wnt/β-catenin
signaling pathway, and other CSC pathways. Promising results from preclinical
trials in human xenograft mice and a few clinical pilote studies reveal that
salinomycin is able to effectively eliminate CSCs and to induce partial clinical
regression of heavily pretreated and therapy-resistant cancers. The ability of
salinomycin to kill both CSCs and therapy-resistant cancer cells may define the
compound as a novel and an effective anticancer drug.